404 related articles for article (PubMed ID: 30203225)
1. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Takehara T; Sakamoto N; Nishiguchi S; Ikeda F; Tatsumi T; Ueno Y; Yatsuhashi H; Takikawa Y; Kanda T; Sakamoto M; Tamori A; Mita E; Chayama K; Zhang G; De-Oertel S; Dvory-Sobol H; Matsuda T; Stamm LM; Brainard DM; Tanaka Y; Kurosaki M
J Gastroenterol; 2019 Jan; 54(1):87-95. PubMed ID: 30203225
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
[TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Curry MP; O'Leary JG; Bzowej N; Muir AJ; Korenblat KM; Fenkel JM; Reddy KR; Lawitz E; Flamm SL; Schiano T; Teperman L; Fontana R; Schiff E; Fried M; Doehle B; An D; McNally J; Osinusi A; Brainard DM; McHutchison JG; Brown RS; Charlton M;
N Engl J Med; 2015 Dec; 373(27):2618-28. PubMed ID: 26569658
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA
Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF; Esteban R; Hyland R; Lu S; Kirby BJ; Meng A; Markova S; Dvory-Sobol H; Osinusi AO; Bruck R; Ampuero J; Ryder SD; Agarwal K; Fox R; Shaw D; Haider S; Willems B; Lurie Y; Calleja JL; Gane EJ
J Hepatol; 2019 Oct; 71(4):660-665. PubMed ID: 31195062
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
[TBL] [Abstract][Full Text] [Related]
11. Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
Asselah T; Shafran SD; Bourgeois S; Lai CL; Mathurin P; Willems B; Nguyen MH; Davis MN; Huang KC; Svarovskaia E; Osinusi A; McNally J; Brainard DM; Shaikh OS; Tran TT
J Viral Hepat; 2019 Oct; 26(10):1229-1232. PubMed ID: 31216086
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Sucher AJ; Hemstreet BA
Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Lawitz E; Poordad F; Wells J; Hyland RH; Yang Y; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Landaverde C; Gutierrez J
Hepatology; 2017 Jun; 65(6):1803-1809. PubMed ID: 28220512
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Wong YJ; Thurairajah PH; Kumar R; Tan J; Fock KM; Law NM; Li W; Kwek A; Tan YB; Koh J; Lee ZC; Kumar LS; Teo EK; Ang TL
J Gastroenterol Hepatol; 2021 May; 36(5):1300-1308. PubMed ID: 33217040
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Foster GR; Afdhal N; Roberts SK; Bräu N; Gane EJ; Pianko S; Lawitz E; Thompson A; Shiffman ML; Cooper C; Towner WJ; Conway B; Ruane P; Bourlière M; Asselah T; Berg T; Zeuzem S; Rosenberg W; Agarwal K; Stedman CA; Mo H; Dvory-Sobol H; Han L; Wang J; McNally J; Osinusi A; Brainard DM; McHutchison JG; Mazzotta F; Tran TT; Gordon SC; Patel K; Reau N; Mangia A; Sulkowski M; ;
N Engl J Med; 2015 Dec; 373(27):2608-17. PubMed ID: 26575258
[TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Flamm S; Lawitz E; Borg B; Charlton M; Landis C; Reddy KR; Shiffman M; Alsina A; Chang C; Ravendhran N; Hernandez C; Hézode C; Scherbakovsky S; Mercier RC; Samuel D
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896803
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
Li JP; Chen XF; Yan Q; Zhang YJ; Xie ZW; Xia Y; Guan YJ
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):831-837. PubMed ID: 33105927
[No Abstract] [Full Text] [Related]
[Next] [New Search]